Compare WGO & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WGO | URGN |
|---|---|---|
| Founded | 1958 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 922.1M |
| IPO Year | N/A | 2017 |
| Metric | WGO | URGN |
|---|---|---|
| Price | $48.69 | $20.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $43.36 | $29.50 |
| AVG Volume (30 Days) | 630.2K | ★ 784.3K |
| Earning Date | 12-19-2025 | 03-09-2026 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $2,875,300,000.00 | $96,516,000.00 |
| Revenue This Year | $5.64 | $26.47 |
| Revenue Next Year | $4.80 | $110.65 |
| P/E Ratio | $38.15 | ★ N/A |
| Revenue Growth | 1.38 | ★ 8.00 |
| 52 Week Low | $28.00 | $3.42 |
| 52 Week High | $50.16 | $30.00 |
| Indicator | WGO | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 49.03 |
| Support Level | $44.58 | $19.13 |
| Resistance Level | $50.16 | $22.21 |
| Average True Range (ATR) | 1.67 | 1.27 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 84.50 | 65.44 |
Winnebago Industries manufactures Class A, B, and C motor homes along with towables, customized specialty vehicles, boats, and parts. Headquartered in Eden Prairie, Minnesota, Winnebago has been producing recreational vehicles since 1958. Revenue was $2.8 billion in fiscal 2025. Winnebago expanded into towables in 2011 with the acquisition of SunnyBrook and acquired Grand Design in November 2016. Towables made up 84% of the firm's RV unit volume, up from 31% in fiscal 2016. The company's total fiscal 2025 RV unit volume was 36,911. Winnebago expanded into boating in 2018 with the purchase of Chris-Craft, bought premium motor home maker Newmar in November 2019, and bought Barletta pontoon boats in August 2021. It also is developing electric and autonomous technology.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.